InvestorsHub Logo
Followers 67
Posts 1293
Boards Moderated 0
Alias Born 08/12/2014

Re: LessIsMore post# 595896

Thursday, 05/25/2023 11:31:41 AM

Thursday, May 25, 2023 11:31:41 AM

Post# of 698717
Exactly right LessIsMore, the earlier in the development of a company, the better chance of being invited to today's moonshot discussion; NWBO is in the process of preparations for regulatory approvals or in the process of regulatory approval, so of course NWBO should not be invited to the discussion, otherwise FDA should be disbanded.

One more example of the above argument is Kazia Therapeutics whose CEO is invited to the discussion as well, which has participated in the global GBM AGILE trial (NCT03970447) with primary completion day of June 2026, contrary to Kazia CEO's claim that its data will be available this year.

The fact is no companies whose trials are completed with positive outcomes are invited to the discussion so you better focus your efforts in reading financial filing, not anything else.

As for whether there is any hint relevant to NWBO from this afternoon's discussion, you will definitely have some as nobody can circumvent NWBO's achievement in this field: soon to be approved paradigm shift caner vaccine DCVax-L, just don't bet on direct name calling.
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News